ADAPTIVE BIOTECHNOLOGIES CORPORATION

Address

1551 EASTLAKE AVE E
SEATTLE, WA, 98102-7402

Information

DUNS: 832591544
# of Employees: 0

Ownership Information

Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N

Award Charts




Award Listing

  1. Correlating TCR diversity to immune reconstitution after cord blood transplant

    Amount: $519,759.00

    DESCRIPTION provided by applicant Many patients requiring stem cell transplantation for hematological malignancies are unable to find a suitable HLA matched sibling or unrelated donor Transplants ...

    SBIRPhase II2017Department of Health and Human Services National Institutes of Health
  2. Non-invasive Diagnostic Platform Development for Celiac Disease Remission Status

    Amount: $244,699.00

    DESCRIPTION (provided by applicant): The purpose of this proposal is to adapt a technology that we have developed for monitoring residual disease in leukemia patients to monitor residual autoimmune di ...

    SBIRPhase I2014Department of Health and Human Services
  3. Minimal Residual Disease Monitoring by T-cell Receptor Repertoire Profiling

    Amount: $165,191.00

    DESCRIPTION (provided by applicant): Minimal Residual Disease Monitoring by T-cell Receptor Repertoire Profiling T-cell neoplasms are generally more aggressive and have poorer outcomes than comparable ...

    SBIRPhase I2013Department of Health and Human Services
  4. Correlating TCR diversity to immune reconstitution after cord blood transplant

    Amount: $2,528,467.00

    DESCRIPTION (provided by applicant): Many patients requiring stem cell transplantation for hematological malignancies are unable to find a suitable HLA-matched sibling or unrelated donor. Transplants ...

    SBIRPhase II2013Department of Health and Human Services
  5. SBIR TOPIC 315: DEVELOPMENT OF COMPANION DIAGNOSTICS: ENABLING PRECISION MEDICINE

    Amount: $266,199.00

    Immunotherapy has emerged as a promising method to treat several cancers. In 2012 the FDA approved a new immunotherapy agent, ipilimumab, for metastatic melanoma. Ipilimumab activates T-cells and glob ...

    SBIRPhase I2013Department of Health and Human Services
  6. Correlating TCR diversity to immune reconstitution after cord blood transplant

    Amount: $148,999.00

    DESCRIPTION (provided by applicant): The goal of this Phase I project is to develop a method to objectively measure immune reconstitution following hematopoietic stem cell transplantation using direc ...

    SBIRPhase I2011Department of Health and Human Services
  7. Development of T-cell receptor repertoire profiling as a diagnostic for T1D

    Amount: $632,685.00

    DESCRIPTION (provided by applicant): The goal of this Phase I project is the identification of a molecular signature in the T-cell receptor repertoire of early-stage Type 1 Diabetes (T1D) patients th ...

    SBIRPhase I2010Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government